N-arylnaphthylamines as inhibitors of human immunodeficiency virus integrase - lens epithelium-derived growth factor interactions: theoretical studies

J Biomol Struct Dyn. 2021 Feb;39(3):867-880. doi: 10.1080/07391102.2020.1719203. Epub 2020 Jan 31.

Abstract

Presented work reports a comprehensive theoretical study on the inhibitory nature of N-arylnaphthylamines in Human Immunodeficiency Virus Integrase (HIV IN) - Lens Epithelium-Derived Growth Factor (LEDGF/p75) complexes. Factors influencing the inhibition efficiency in AlphaScreen% assay are evaluated and explained through the structure- and ligand-based studies; including molecular docking, molecular dynamics calculations, and quantitative structure-activity relationship (QSAR) approach. It has been shown that N-arylnaphthylamines possess a wide variety of binding poses. Three QSAR models have been developed using structural descriptors and descriptors derived from docking calculations. The activity of untested N-arylnaphthylamines have been predicted using the most successful model. Proposed here technique could become a useful tool for ligand selection, accelerating the development of a new generation of anti-HIV medications. [Formula: see text] Communicated by Ramaswamy H. Sarma.

Keywords: HIV; LEDGF/p75-HIV integrase; N-arylnaphthylamines; QSAR; molecular docking; molecular dynamics.

MeSH terms

  • HIV
  • HIV Infections*
  • HIV Integrase Inhibitors* / pharmacology
  • HIV Integrase*
  • Humans
  • Intercellular Signaling Peptides and Proteins
  • Molecular Docking Simulation

Substances

  • HIV Integrase Inhibitors
  • Intercellular Signaling Peptides and Proteins
  • lens epithelium-derived growth factor
  • HIV Integrase